Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide

RNA

Volumn 15, Issue 4, 2009, Pages 627-636

  Detzer, Anke ^a   Overhoff, Marita ^a,c   Wünsche, Winfried ^a   Rompf, Maria ^a,d   Turner, John J ^b,e   Ivanova, Gabriela D ^b   Gait, Michael J ^b   Sczakiel, Georg ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e NOXXON PHARMA AG   (Germany)

Author keywords

Conjugation; Delivery; Phosphorothioate; Subcellular; Trafficking

Indexed keywords

BACTERIAL PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ARTICLE; CYTOPLASM; CYTOTOXICITY; MEMBRANE TRANSPORT; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SYNTHESIS;

CELL LINE, TUMOR; HUMANS; LAMININ; PROTEIN SORTING SIGNALS; RNA INTERFERENCE; RNA TRANSPORT; RNA, SMALL INTERFERING;

BACTERIA (MICROORGANISMS);

EID: 62549161328     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.1305209     Document Type: Article

References (44)

1. Adam, S.A. and Gerace, L. 1991. Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import. Cell 66: 837-847.
2. Bonifacino, J.S. and Glick, B.S. 2004. The mechanisms of vesicle budding and fusion. Cell 116: 153-166.
3. Bos, K., Wraight, C., and Stanley, K.K. 1993. TGN38 is maintained in the trans-Golgi network by a tyrosine-containing motif in the cytoplasmic domain. EMBO J. 12: 2219-2228.
4. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D.W. 2006. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem. Biol. 2: 711-719.
5. Cheng, K., Ye, Z., Guntaka, R.V., and Mahato, R.I. 2006. Enhanced hepatic uptake and bioactivity of type α 1(I) collagen gene promoter- specific triplex-forming oligonucleotides after conjugation with cholesterol. J. Pharmacol Exp. Ther. 317: 797-805.
6. de Fougerolles, A., Vornlocher, H.P., Maraganore, J., and Lieberman, J. 2007. Interfering with disease: A progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6: 443-453.
7. Deshayes, S., Morris, M., Hertz, F., and Divita, G. 2008. Delivery of proteins and nucleic acids using a noncovalent peptide-based strategy. Adv. Drug Deliv. Rev. 60: 537-547.
8. Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475-1489.
9. Dorsett, Y. and Tuschl, T. 2004. siRNAs: Applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 3: 318-329.
10. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T. 2001. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20: 6877-6888.
11. Elbashir, S.M., Harborth, J., Weber, K., and Tuschl, T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213.
12. Falnes, P.O. and Sandvig, K. 2000. Penetration of protein toxins into cells. Curr. Opin. Cell Biol. 12: 407-413.
13. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H.N., and Chen, J. 2004. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. 101: 8676-8681.
14. Grzelinski, M., Urban-Klein, B., Martens, T., Lamszus, K., Bakowsky, U., Hobel, S., Czubayko, F., and Aigner, A. 2006. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17: 751-766.
15. Haney, S.A. 2007. Expanding the repertoire of RNA interference screens for developing new anticancer drug targets. Expert Opin. Ther. Targets 11: 1429-1441.
16. Hannon, G.J. 2002. RNA interference. Nature 418: 244-251.
17. Humphrey, J.S., Peters, P.J., Yuan, L.C., and Bonifacino, J.S. 1993. Localization of TGN38 to the trans-Golgi network: Involvement of a cytoplasmic tyrosine-containing sequence.J. CellBiol 120:1123-1135.
18. Kretschmer-Kazemi Far, R. and Sczakiel, G. 2003. The activity of siRNA in mammalian cells is related to structural target accessibility: A comparison with antisense oligonucleotides. Nucleic Acids Res. 31: 4417-4424.
19. Le, P.U. and Nabi, I.R. 2003. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum.J. Cell Sci. 116: 1059-1071.
20. Lebleu, B., Moulton, H.M., Abes, R., Ivanova, G.D., Abes, S., Stein, D.A., Iversen, P.L., Arzumanov, A.A., and Gait, M.J. 2008. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60: 517-529.
21. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., and Tuschl, T. 2002. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110: 563-574.
22. Meister, G., Landthaler, M., Dorsett, Y., and Tuschl, T. 2004. Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing. RNA 10: 544-550.
23. Mescalchin, A., Detzer, A., Wecke, M., Overhoff, M., Wiinsche, W., and Sczakiel, G. 2007. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: Novel options by phosphorothioate- stimulated delivery. Expert Opin. Biol. Ther. 7: 1531-1538.
24. Minakuchi, Y., Takeshita, F., Kosaka, N., Sasaki, H., Yamamoto, Y., Kouno, M., Honma, K., Nagahara, S., Hanai, K., Sano, A., et al. 2004. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32: el09. doi: 10.1093/nar/gnh093.
25. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23: 1002-1007.
26. Munro, S. and Pelham, H.R. 1987. A C-terminal signal prevents secretion of luminal ER proteins. Cell 48: 899-907.
27. Opalinska, J.B. and Gewirtz, A.M. 2002. Nucleic-acid therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov. 1: 503-514.
28. Overhoff, M. and Sczakiel, G. 2005. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep. 6: 1176-1181.
29. Overhoff, M., Wünsche, W., and Sczakiel, G. 2004. Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA. Nucleic Acids Res. 32: el70. doi: 10.1093/nar/gnhl68.
30. Rana, T.M. 2007. Illuminating the silence: Understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8: 23-36.
31. Ratts, R., Trujillo, C., Bharti, A., vanderSpek, J., Harrison, R., and Murphy, J.R 2005. A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proc. Natl. Acad. Sci. 102: 15635-15640.
32. Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V., Fisch, G., Dames, S., Loffler, K., Fechtner, M., Arnold, W., et al. 2006. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13: 1222-1234.
33. Song, E., Lee, S.K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., and Lieberman, J. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9: 347-351.
34. Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., et al. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23: 709-717.
35. Soutschek, J., AkinC., A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
36. Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. 2005. Efficient delivery of small interfering RNA to bone- metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. 102: 12177-12182.
37. Takizawa, P.A., Yucel, J.K., Veit, B., Faulkner, D.J., Deerinck, T., Soto, G., Ellisman, M., and Malhotra, V. 1993. Complete vesicu- lation of Golgi membranes and inhibition of protein transport by a novel sea sponge metabolite, ilimaquinone. Cell 73: 1079-1090.
38. Tan, P.H., Yang, L.C., Shih, H.C., Lan, K.C., and Cheng, J.T. 2005. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 12: 59-66.
39. Turner, J.J., Williams, D., Owen, D., and Gait, M.J. 2006. Disulfide conjugation of peptides to oligonucleotides and their analogs. In Current protocols in nucleic acid chemistry, Chap. 4, pp. 4.28.21-24.28.21. Wiley, New York.
40. Turner, J.J., Jones, S., Fabani, M.M., Ivanova, G., Arzumanov, A.A., and Gait, M.J. 2007. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol. Dis. 38: 1-7.
41. Vomlocher, H.P. 2006. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol. Med. 12: 1-3.
42. Wang, H.J., Benlimame, N., and Nabi, I. 1997. The AMF-R tubule is a smooth ilimaquinone-sensitive subdomain of the endoplasmic reticulum. J. Cell Sci. 110: 3043-3053.
43. Zamore, P.D. and Haley, B. 2005. Ribo-gnome: The big world of small RNAs. Science 309: 1519-1524.
44. Zeng, Y. and Cullen, B.R. 2002. RNA interference in human cells is restricted to the cytoplasm. RNA 8: 855-860.